London-listed PRTech firm Pathos Communications has built a proprietary AI platform, PathosMind, for internal use by its employees and partners. The system is designed to identify stories that ...

London-listed PRTech firm Pathos Communications has created PathosMind, a proprietary AI platform built exclusively for use by its employees and partners. The platform is designed to identify stories ...

Pathos is a technology-enabled, human-led PR company. The Company collaborates with its clients to create and distribute articles and media across a variety of platforms, including established news ...

A British marketing agency ranked among Europe's fastest-growing businesses is planning to float on the London Stock Exchange later this month, The Mail on Sunday understands. Pathos Communications, ...

(Alliance News) - Public relations agency Pathos Communications Ltd on Tuesday shared plans for an initial public offering on AIM later this month. The UK-incorporated firm expects admission to the ...

Until last week Monday, I had a sometimes grudging, but deep respect for Larry Summers, as one of the most insightful economists of the modern era. I had previously brushed aside some of his previous ...

One of the aims of anthropology is to promote human self-understanding, that is, to activate a process of awareness of the existential and cultural dynamics we experience. This is a liberating process ...

The newspaperman of fiction is either “hardboiled” or a cub in the seventh heaven of innocence. But the newspaperman in life is generally a man whose chief interest is his own business of gathering ...

Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding. The company didn’t disclose the ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pathos AI, the biotech drug developer spun out of Tempus ...

Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics. The ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Chicago-grown biotech firm ...